Quinazolinones as prolyl hydroxylase inhibitors

US8937078B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Scott D. Bembenek · San Diego, US
• Frances Meredith Hocutt · San Diego, US
• Barry Eastman Leonard, Jr. · Village of La Jolla, US
• Michael H. Rabinowitz · San Diego, US
• Mark D. Rosen · San Diego, US
• Kyle T. Tarantino · Princeton, US
• Hariharan Venkatesan · San Diego, US

Key dates

• Filing date: Feb 10, 2010
• Grant date: Jan 20, 2015
• Expiry date: Aug 14, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Quinazolinone compounds of formula (I) are described,which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.